David A. Siegel Blueprint Medicines Corp Transaction History

Two Sigma Advisers, LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$37.97 - $50.0 $1.09 Million - $1.44 Million	-28,700 Reduced 37.81%	47,200 $2.12 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $574,840 - $930,720	14,000 Added 22.62%	75,900 $3.33 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $3.09 Million - $4.81 Million	61,900 New	61,900 $4.08 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $3.54 Million - $6.05 Million	-73,600 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $2.9 Million - $3.59 Million	-43,500 Reduced 37.15%	73,600 $5.9 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $211,410 - $294,089	2,900 Added 2.54%	117,100 $8.6 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $161,788 - $215,160	-2,200 Reduced 1.89%	114,200 $10.8 Million
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $2.09 Million - $3.72 Million	-42,900 Reduced 26.93%	116,400 $9.32 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $104,811 - $170,798	-2,300 Reduced 1.42%	159,300 $8.59 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $3.85 Million - $5.12 Million	-65,400 Reduced 28.81%	161,600 $12.6 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $9.25 Million - $15.4 Million	151,800 Added 201.86%	227,000 $14.4 Million
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $454,336 - $638,290	-6,200 Reduced 7.62%	75,200 $6.9 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $2.42 Million - $3.39 Million	38,400 Added 89.3%	81,400 $6.14 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $1.82 Million - $3 Million	43,000	43,000 $3 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.